As a young company, it is perhaps too early in our development to compare SK Plasma with the leading global plasma companies. However, one distinctive strength…
In Conversation
Thanks to their versatility, oncolytic viruses can, therefore, be very potent. Our Invir.IO™ platform will be revolutionary for tumours that resist currently available treatments.
At UCB, we want to deliver the highest value to patients from diagnosis through to treatment, co-creating solutions with them
The acquisition of Shire products also allowed us to enter the US market, a key point in our ambition to increase our global presence
One of the biggest challenges that Vygon is facing is that the health authorities know very little about medical devices
Recently, we have witnessed some profound policy developments that move us closer towards the holy grail of a learning healthcare system
Science is the most important asset of Ferring and my education has encouraged me to be science-driven
This is both a hopeful and terrifying time to be a patient in the USA
Today’s patients are much more involved in the health paradigm than they used to be, and this must be acknowledged by the industry
There is a tremendously broken data supply chain, which will trigger social uproar when the public are made aware of it
In the US, Jazz is already known for its leadership in sleep medicine. It is our expertise here that we will be bringing to France and…
Life sciences is not the company’s primary activity, but it remains a good way to keep our teams busy when the oil and gas market is…
